In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

by Neelesh Sharma, Alex A. Adjei
Published 2011-11-01

JTO Clinical and Research Reports Is Born

by Alex A. Adjei, MD, PhD
Published 2020-03-01

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

by Yan W. Asmann, Kaushal Parikh, P. Leif Bergsagel, Haidong Dong, Alex A. Adjei, Mitesh J. Borad, Aaron S. Mansfield
Published 2021-03-01

Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma

by Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A Adjei, Jeffrey N Miner, Dominik Mumberg, Karl Ziegelbauer, Arne Scholz
Published 2013-10-01

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events

by Sidra Anwar, Wei Tan, Chi-Chen Hong, Sonal Admane, Askia Dozier, Francine Siedlecki, Amy Whitworth, Ann Marie DiRaddo, Dawn DePaolo, Sandra M. Jacob, Wen Wee Ma, Austin Miller, Alex A. Adjei, Grace K. Dy
Published 2017-06-01